Gilead Sciences, Inc. (NASDAQ) on Tuesday released results from the Phase 3 IDEAL study in people with primary biliary cholangitis (PBC).
The study showed that treatment with Livdelzi (seladelpar) resulted in significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker associated with disease progression, compared with placebo after 52 weeks.
Something went wrong.
The primary endpoint was defined as a composite of ALP ≤1.0× the upper limit of normal (ULN) and a ≥15% decrease from baseline.
Results Support Use In Underrepresented PBC Patient Population
